Vitamin D3 for Life

Live Enlightened

Physiology

Maternal Vitamin D Adaptations During Pregnancy: Full Evidence Review

Previous related pageMaternal Vitamin D Adaptations During Pregnancy: Study SummaryNext related pageHow to Read Vitamin D Studies During Pregnancy
Study at a glance

What was the question?

How do vitamin D measurements change during pregnancy? The review separates 25-hydroxyvitamin D, the usual blood marker, from calcitriol, the active hormone, and the proteins that carry vitamin D.

Who was studied?

Seven investigations studied pregnant adults and adolescents. Some followed the same people over time. Others compared different people at different pregnancy stages. One trial assigned different vitamin D3 supplement amounts.

What did the studies find?

Active-hormone concentrations were higher in a small early study. The usual status marker rose in some groups and fell in another. Season and other differences affected interpretation. A study of 58 adolescents found no significant average change in directly measured free 25-hydroxyvitamin D between entry and delivery. Free means the amount not attached to carrier proteins.

What does this mean?

Different vitamin D measurements cannot be treated as one result. Calculated free amounts are not the same as direct measurements. Supplements changed blood status, but this did not establish a guaranteed health benefit. The studies do not prove one universal pregnancy pattern, personal blood target or supplement dose.

Read the full article below ↓

Pregnancy changes vitamin D physiology, but it does not produce one predictable pattern in every blood measurement. The active hormone, the main status marker and the proteins that carry vitamin D can change differently. This review examines seven human investigations to distinguish measured maternal adaptation from assumptions about requirements or health benefits. For the shorter account, read Maternal Vitamin D Adaptations During Pregnancy: Study Summary.

Three measurements that answer different questions

Vitamin D3 supplied in a supplement is not the same substance as either of the blood measurements discussed here. The main status marker is 25-hydroxyvitamin D, written as 25(OH)D. The active hormone is 1,25-dihydroxyvitamin D, also called calcitriol. An increase in active hormone does not establish that the circulating status marker increased by the same amount. The distinction is explained in Vitamin D Testing: 25-OH-D vs 1,25-OH₂-D.

Most circulating vitamin D metabolites are attached to carrier proteins. A measurement of total concentration includes bound and unbound material. A free measurement concerns the small unbound fraction. Calculated free concentrations use total concentration, protein measurements and binding assumptions; they are not direct measurements of that fraction. Vitamin D Transport Proteins explains the carrier system, while Free Versus Total Vitamin D Measurement and Interpretation: Full Study examines why calculation and direct measurement cannot simply substitute for one another.

These distinctions matter during pregnancy because gestational age, carrier concentrations, season, supplements and analytical methods can all differ between observations. A blood sample describes a particular circulating compartment at a particular time. It does not directly measure every tissue’s activation of vitamin D, the amount of calcium absorbed from food, or the success of a pregnancy. The underlying processing of vitamin D is introduced in Vitamin D Metabolism at the Cellular Level.

Active hormone: an early observation with a limited causal explanation

Kumar and colleagues’ 1979 study included 31 pregnant women, six lactating women and ten age-matched female controls. Four pregnant participants were followed longitudinally. Active-hormone concentrations were higher in pregnancy, and the mostly cross-sectional data showed a positive relationship with gestational duration. First-trimester mean concentration was about 87 pg/mL, compared with about 53 pg/mL in controls, with substantial variation around those means.

This was useful evidence that pregnancy alters circulating active-hormone physiology. It was not a direct demonstration of the mechanism producing the higher concentration. Greater production and slower removal are different explanations, and the study did not establish which process accounted for the observations. It also did not measure intestinal calcium absorption or prove that a higher active-hormone concentration caused a particular maternal or fetal benefit.

The design limits the strength of the temporal conclusion. Most observations came from different women rather than repeated sampling of the same women. The assay was a historical binding method, and the sample was small. Three of the four longitudinal cases showed an increase; that is not evidence that every pregnancy follows an identical curve. A small subset’s unchanged status-marker comparison likewise cannot establish equivalence. 25-Hydroxyvitamin D and 1,25-Dihydroxyvitamin D: Physiological Meaning and Regulation: Full Study provides the broader distinction between active-hormone regulation and vitamin D status.

Binding and gestational age: association is not a trajectory

Tsuprykov and colleagues examined 427 healthy pregnant women from the Berlin Birth Cohort in a cross-sectional study. Samples were collected in May and June. The investigators measured total vitamin D metabolites and binding protein, then calculated free and bioavailable fractions. They compared women at different gestational stages rather than following each participant through all three trimesters.

Total calcitriol and vitamin D-binding protein were higher at later gestational stages. Total 25(OH)D did not show a significant trimester difference, while calculated free 25(OH)D was lower later in pregnancy. These findings demonstrate why different measurements should not be described as a single “vitamin D level.” They also illustrate how a calculated fraction depends on the protein and total-concentration measurements used to derive it.

The correlations do not establish that free testing predicts clinical outcomes better. Gestational age, albumin, dilution and the calculation itself can contribute to relationships between variables. Many comparisons were examined, and the reported trimester counts do not sum exactly to the overall sample. The study supports a qualified description of between-group biochemical relationships, not a proven within-person mechanism or a pregnancy-specific diagnostic target.

Directly measured free vitamin D gives a useful qualification

Best and colleagues followed a multiracial cohort of pregnant adolescents in Rochester, New York. The analysis included 58 adolescents with complete longitudinal biochemical data. Samples were obtained around the middle of pregnancy, later pregnancy and delivery. Free 25(OH)D was measured directly at entry and delivery, rather than calculated from total concentration and binding assumptions.

Binding protein changed over pregnancy, but mean measured free 25(OH)D did not show a significant entry-to-delivery change: the adjusted means were approximately 4.34 and 4.43 pg/mL. Conditional analyses found that increasing binding protein was associated with somewhat lower free concentration when total 25(OH)D was taken into account. That relationship must not be rewritten as a demonstrated fall in the group’s average free concentration.

The active-hormone pattern also qualified a simple steady-rise account. Adjusted calcitriol concentrations were higher at the middle observation than at delivery. Different timing, age, assays and exposure could help explain why this pattern differs from an older cross-sectional study. The studies do not need to agree on one universal curve to demonstrate that pregnancy-related vitamin D physiology is dynamic.

This was an ancillary observational analysis within a supplementation cohort. It did not randomize women to different binding-protein concentrations. Adherence to supplements was limited, and the sample excluded participants without complete biochemical observations. There was no early-pregnancy baseline or clinical-outcome test. Total 25(OH)D was at least as strongly related to the assessed systemic biomarkers as free 25(OH)D; neither result establishes the better test for every tissue or clinical question.

Longitudinal total-status studies do not all point in the same direction

In Sweden, Lundqvist and colleagues studied 184 women who supplied at least three samples from early pregnancy through seven months after birth. Mean total 25(OH)D rose from about 55 nmol/L in early pregnancy to about 65 nmol/L later in pregnancy, then fell after delivery. Individual patterns varied substantially, and season was strongly associated with concentration.

Repeated sampling strengthens the description of change within this cohort. It does not remove seasonal confounding or supply a contemporary nonpregnant control group. Intake estimates relied on questionnaires, and individual sun exposure and travel were not fully characterized. The result is a pregnancy-associated trajectory under the circumstances studied, rather than proof that pregnancy itself necessarily raises total 25(OH)D.

Zhang and colleagues found a different pattern in 30 low-risk, first-pregnancy participants from the Irish SCOPE cohort. These women were recruited during the warmer months and delivered in winter. Total 25(OH)D declined from about 50 nmol/L at 15 weeks to about 37 nmol/L at 36 weeks. Binding protein rose and later fell, while calculated free concentrations also changed.

The Irish study does not establish that pregnancy necessarily lowers vitamin D status. Its seasonal design is an important alternative explanation, just as season matters when interpreting the Swedish increase. The sample was small and had no contemporary nonpregnant comparison. Reading the two investigations together is more informative than choosing whichever direction supports a preferred claim. Why Vitamin D Blood Test Results Need Context explains why timing and measurement conditions belong in interpretation of any result.

Agudelo-Zapata and colleagues added observations from Bogotá. Their longitudinal comparison included 61 healthy pregnancies and 20 pregnancies that later developed preeclampsia without severity features. Mean total 25(OH)D increased across the healthy group’s trimesters, but the study did not detect a trimester-specific difference between the healthy and preeclamptic groups. The selected sample, co-supplementation and uncharacterized sunlight and dietary calcium restrict generalization.

The preeclampsia comparison is not proof that vitamin D status is irrelevant to every pregnancy complication. It is a measured null in a particular observational study. Equally, the rising status-marker concentration does not explain active-hormone production, absorption or clinical protection, because those were different questions from the one measured.

Randomized supplementation separates exposure response from adaptation

Hollis and colleagues compared three daily vitamin D3 regimens from about 12 to 16 weeks until delivery. The assigned totals were 400, 2,000 and 4,000 international units, including the prenatal supplement contribution. These are descriptions of research exposure, not personal dosing instructions. The principal endpoint concerned biochemical status rather than proof of a clinical pregnancy benefit.

Higher assigned exposure increased measured 25(OH)D and attainment of the study-defined threshold of at least 80 nmol/L. Using delivery measurements, or the preceding month’s value when delivery data were missing, 57 of 109 participants (52.3%), 93 of 117 (79.5%) and 94 of 112 (83.9%) reached that threshold in the assigned 400, 2,000 and 4,000 international-unit groups, respectively. However, the higher two groups did not differ significantly in the combined endpoint’s threshold attainment. That threshold was a study definition; it does not become a universal target merely because researchers used it to compare groups.

Follow-up was incomplete. The principal body reports 502 randomized participants and 350 continuing through delivery, while its abstract uses a different enrollment count. The analyzed sample was consequently not a complete follow-up of every randomized participant. Adherence was also imperfect, and the combined endpoint did not represent a delivery measurement for every participant. These features matter when estimating how reliably an assigned exposure predicts an observed concentration.

The study did not establish significant group differences in gestational age, birthweight or higher-level neonatal care. Its size, selection and timing limit clinical and safety conclusions. It demonstrates that changing exposure can change circulating status during pregnancy. It does not show that every higher concentration improves maternal or infant health. Vitamin D Status vs Vitamin D Effect explains this difference between a status measurement and a biological or clinical effect.

What the seven studies establish together

QuestionWhat the assessed evidence supportsWhat it does not establish
Does active hormone change?Pregnancy-associated differences and time-dependent patterns in selected cohortsOne universal curve or the responsible causal mechanism
Does total status always rise?Different trajectories across settings, with important seasonal and exposure influencesA change caused by pregnancy alone
Is free status different from total status?Binding and assay choice affect their relationshipUniversal superiority of free testing
Does supplementation alter status?Randomized exposure can alter measured 25(OH)DA personal target or guaranteed health benefit

The strongest interpretation preserves the differences between these studies. Cross-sectional comparisons, longitudinal observations and randomized exposure answer different questions. Directly measured and calculated free concentrations are not interchangeable. Adolescents, selected adult cohorts and trial participants do not automatically represent every pregnancy. Concentration, production, tissue action and clinical outcome remain separate levels of evidence.

This review is a selected assessment of maternal physiology, not a systematic review or clinical guideline. It supports an explanation of pregnancy-related adaptation without making every observed change an effect of pregnancy itself. Material uncertainty remains about causal drivers, generalization across populations and the clinical meaning of free measurements. Those uncertainties are part of the scientific result, rather than reasons to replace the evidence with a single “optimal level.”

Sources and access

Principal papers and claim-relevant material were assessed. Uninspected plots from Best, Hollis and Agudelo are not used for graph-derived thresholds or additional claims. Hollis is read with its neonatal-unit correction; disputed ranges are omitted. Tsuprykov’s calculated fractions are distinguished from Best’s direct measurements. Related reports from the same cohort are not counted as independent confirmations.

Elevated 1,25-dihydroxyvitamin D plasma levels in normal human pregnancy and lactation. Kumar R et al. Journal of Clinical Investigation. 1979;63:342 to 344.

Opposite correlation of 25-hydroxy-vitamin D: and 1,25-dihydroxy-vitamin D-metabolites with gestational age, bone: and lipid-biomarkers in pregnant women. Tsuprykov O et al. Scientific Reports. 2021;11:1923.

Longitudinal Changes in Serum Vitamin D Binding Protein and Free 25-hydroxyvitamin D in a Multiracial Cohort of Pregnant Adolescents. Best CM et al. Journal of Steroid Biochemistry and Molecular Biology. 2019;186:79 to 88.

Vitamin D Status during Pregnancy: A Longitudinal Study in Swedish Women from Early Pregnancy to Seven Months Postpartum. Lundqvist A et al. PLOS ONE. 2016;11:e0150385.

Impact of pregnancy on vitamin D status: a longitudinal study. Zhang JY et al. British Journal of Nutrition. 2014;112:1081 to 1087.

Serum 25-hydroxyvitamin D levels throughout pregnancy: a longitudinal study in healthy and preeclamptic pregnant women. Agudelo-Zapata Y et al. Endocrine Connections. 2018;7:698 to 707.

Vitamin D Supplementation during Pregnancy: Double Blind, Randomized Clinical Trial of Safety and Effectiveness. Hollis BW et al. Journal of Bone and Mineral Research. 2011;26:2341 to 2357. Correction: Erratum: Vitamin D supplementation during pregnancy: Double-blind, randomized clinical trial of safety and effectiveness. 2011.

Related reading

Library

Diverse Effects of Combinations of Maternal-Neonatal VDR Polymorphisms and 25-Hydroxyvitamin D Concentrations on Neonatal Birth Anthropometry: Functional Phenocopy Variability Dependence, Highlights the Need for Targeted Maternal 25-Hydroxyvitamin D Cut-Offs during Pregnancy

The aim of this study was to evaluate the combined effect of maternal and neonatal VDR polymorphisms (ApaI, TaqI, BsmI, FokI, Tru9I) and different maternal and neonatal 25(OH)D cut-offs on neonatal birth anthropometry.

Original paper ↗Read more →

Original sources

Source

Vitamin D Supplementation during Pregnancy: Double Blind, Randomized Clinical Trial of Safety and Effectiveness

Published in Hollis BW et al. Journal of Bone and Mineral Research (2011).

Publication details

Vitamin D Supplementation during Pregnancy: Double Blind, Randomized Clinical Trial of Safety and Effectiveness. Hollis BW et al. Journal of Bone and Mineral Research. 2011;26:2341 to 2357. Correction: Erratum: Vitamin D supplementation during pregnancy: Double-blind, randomized clinical trial of safety and effectiveness. 2011.

Read more →
Source

Erratum: Vitamin D supplementation during pregnancy: Double-blind, randomized clinical trial of safety and effectiveness

Vitamin D Supplementation during Pregnancy: Double Blind, Randomized Clinical Trial of Safety and Effectiveness.

Publication details

Vitamin D Supplementation during Pregnancy: Double Blind, Randomized Clinical Trial of Safety and Effectiveness. Hollis BW et al. Journal of Bone and Mineral Research. 2011;26:2341 to 2357. Correction: Erratum: Vitamin D supplementation during pregnancy: Double-blind, randomized clinical trial of safety and effectiveness. 2011.

Read more →